The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
LLM 2021 | Emerging therapeutic options for Hodgkin lymphoma
Jonathan Friedberg, MD MMSc, Wilmot Cancer Center, University of Rochester, Rochester, NY, discusses the emerging therapeutic strategies that seem most promising for the treatment of Hodgkin lymphoma. A large collaborative group in North America is progressing on a clinical trial that will test the combination of AVD (doxorubicin, vinblastine, dacarbazine) with either brentuximab or nivolumab in a considerable number of newly diagnosed Hodgkin lymphoma patients. Its results are expected to be highly informative of the optimal place for the regimens studied in the upfront setting. There are also plans for a clinical trial in the relapse group of patients, which is expected to shed light on the benefits of including checkpoint inhibitors in the context of salvage therapy prior to autologous stem cell transplantation. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
